Alirocumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Alirocumab" in French language version.

refsWebsite

Global rank French rank

4sciencedirect.com

149^th place

80^th place

3nejm.org

2,374^th place

298^th place

2doi.org

2^nd place

3^rd place

2jamanetwork.com

2,650^th place

689^th place

1who.int

195^th place

221^st place

1nih.gov

4^th place

12^th place

1wikipedia.org

low place

1oup.com

485^th place

416^th place

1ahajournals.org

3,608^th place

659^th place

1europa.eu

68^th place

67^th place

1healthaffairs.org

low place

ahajournals.org

Pérez de Isla L, Díaz-Díaz JL, Romero MJ et al. Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: The ARCHITECT study, Circulation, 2023;147:1436–1443

doi.org

dx.doi.org

C. Sheridan, « Phase 3 data for PCSK9 inhibitor wows », Nature Biotechnology, vol. 31, n^o 12,‎ 2013, p. 1057-1058 (PMID 24316621, DOI 10.1038/nbt1213-1057, lire en ligne) modifier
(en) William H. Shrank, Jane F. Barlow, Troyen A. Brennan, « New Therapies in the Treatment of High Cholesterol », JAMA,‎ 10 août 2015 (DOI 10.1001/jama.2015.10017, lire en ligne).

europa.eu

ema.europa.eu

(en) « Praluent recommended for approval to lower cholesterol », sur ema.europa.eu, EMA, 24 juillet 2015 (consulté le 31 août 2015).

healthaffairs.org

(en) William Shrank, Alan Lotvin, Surya Singh et Troyen Brennan, « In The Debate About Cost And Efficacy, PCSK9 Inhibitors May Be The Biggest Challenge Yet », sur healthaffairs.org, 17 février 2015 (consulté le 5 septembre 2015).

jamanetwork.com

Räber L, Ueki Y, Otsuka T et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial, JAMA, 2022;327:1771-1781

jama.jamanetwork.com

(en) William H. Shrank, Jane F. Barlow, Troyen A. Brennan, « New Therapies in the Treatment of High Cholesterol », JAMA,‎ 10 août 2015 (DOI 10.1001/jama.2015.10017, lire en ligne).

nejm.org

Stein EA, Mellis S, Yancopoulos GS et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol, N Engl J Med, 2012;366:1108-1118
Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, 2015;372:1489-1499
Schwartz GG, Steg PG, Szarek M et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med, 2018;379:2097-2107

nih.gov

ncbi.nlm.nih.gov

C. Sheridan, « Phase 3 data for PCSK9 inhibitor wows », Nature Biotechnology, vol. 31, n^o 12,‎ 2013, p. 1057-1058 (PMID 24316621, DOI 10.1038/nbt1213-1057, lire en ligne) modifier

oup.com

academic.oup.com

White HD, Schwartz GG, Szarek M et al. Alirocumab after acute coronary syndrome in patients with a history of heart failure, Eur Heart J, 2022;43:1554–1565

sciencedirect.com

McKenney JM, Koren MJ, Kereiakes DJ et al. Safety and efficacy of a monoclonal antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy, J Am Coll Cardio, 2012;59:2344–2353
Jukema JW, Szarek M, Zijlstra LE et al. Alirocumab in patients With polyvascular disease and recent acute coronary syndrome, J Am Coll Cardiol, 2019:74:1167-1176
Goodman SG, Aylward PE, Szarek M et al. Effects of Alirocumab on cardiovascular events after coronary bypass surgery, J Am Coll Cardiol, 2019;74:1177-1186
(en) Robinson JG, Rosenson RS, Farnier M et al. « Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials » J Am Coll Cardiol. 2017;69:471–482.

who.int

International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization

wikipedia.org

fr.wikipedia.org

C. Sheridan, « Phase 3 data for PCSK9 inhibitor wows », Nature Biotechnology, vol. 31, n^o 12,‎ 2013, p. 1057-1058 (PMID 24316621, DOI 10.1038/nbt1213-1057, lire en ligne) modifier